Ann: Brazilian Patent Issued for Lung & Colorectal Cancer, page-3

IMHO, SDX was a reverse-takeover, the current board 'direction' isn't necessarily completely-aligned to realising SH-value for 'all' SH (us), just the select few that are of the firm belief that the Sub2M/EXONET streams offer more 'opportunity' (think LTI, STI KPI-targets embedded into merger-terms, etc) than the BARD1 (Aab) stream, noting that there is still 'highly-contentious' litigation brewing in the background...

As I've suggested, I suspect there some 'very big EGO's' stepped aboard during the SDX/BD1 merger, founding directors/scientists don't 'walk-away' from their 'life's work' for nothing, as we're observing (although without much transparency, despite disclosure obligations)...

More BD1 (Aab) patents to poke a stick at to protect a work-stream they've 'starved' of CAPEX for their own 'perceived' interests, I won't be re-electing any of the current directors without some form of transparency around why/how (NPV, ROI, TCO, etc) they 'allocate' CAPEX to work-streams...

To me, something doesn't quite seem 100% right, bit grubby...